Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EMS
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed Consent of the patient;
Participants with decompensated essential hypertension, classified into stage 1 (with high or very high cardiovascular risk), stage 2 or stage 3 according to the Brazilian Society of Cardiology (2010), who have never been treated and have indication for drug combination treatment.
Obs: The diagnosis may be established by previous evaluation of two blood pressure measures ≥ 140/90 mmHg, with two months difference between measurements
You may not be if
Patients with any clinically significant disease that in the investigator is opinion can not participate in the study;
Secondary hypertension diagnosis or blood pressure above 190x100 mmHg in the screening/randomization visit;
Morbid obesity or immunocompromised patients;
Participants with greater than 10 mmHg difference in the measurements of systolic or diastolic blood pressure between the two arms;
Participants who do not have the two upper limbs;
Participants with important electrocardiographic changes;
Creatinine clearance - less than 60 mL /min;
History of hypertensive emergencies and cardiovascular and / or moderate to severe cerebrovascular events in the past 6 months;
Microalbuminuria in urine sample greater than 30 mg/g;
Patients with history of hypersensitivity to any of the formula compounds;
Pregnancy or risk of pregnancy and lactating patients;
Participation in clinical trial in the year prior to this study.
Clareo Health | Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
